Study Probes Role of Sestrin 3 in Glucose Metabolism and Diabetes Development
By LabMedica International staff writers Posted on 18 Nov 2014 |
Image: The Sestrin 3 protein, labeled in red fluorescence and shown interacting with other proteins (highlighted in yellow) in the liver, may have implications in treating type II diabetes (Photo courtesy of the Indiana University School of Medicine).
A recent paper discussed the role of sestrin proteins in resisting oxidative stress and regulating metabolic processes such as glucose production and insulin sensitivity, which are disrupted in type II diabetes and metabolic syndrome.
Investigators at Indiana University School of Medicine (Indianapolis, USA) focused their attention on the protein Sestrin 3 (Sesn3). The gene for this protein in humans is located on chromosome 11q21. The sestrin family of proteins, of which Sesn3 is a member, comprises cysteine sulfinyl reductases, and they modulate peroxide signaling and antioxidant defense. These proteins selectively reduce or repair hyperoxidized forms of typical 2-cysteine peroxiredoxins (enzymes that metabolize peroxides) in eukaryotes.
Sestrin expression was found to be regulated by the tumor suppressor protein p53. Sesn3 was identified as a forkhead box O (FoxO) protein with antioxidant activity. Recently it was reported that Sesn3 may play an important role in Akt induced increase in reactive oxygen species (ROS), and it might be a promising target in selectively killing cancer cells containing high levels of Akt activity.
Akt, also known as protein kinase B (PKB), is a serine/threonine-specific protein kinase that plays a key role in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription, and cell migration. Akt is hyperactivated in cancer. This hyperactivity leads to an increase in intracellular ROS mainly by inhibiting the expression of ROS scavengers downstream of FoxO, such as Sesn3.
In the current study, the investigators generated Sesn3 liver-specific transgenic and knockout mice. These animals were fed a diet with 18% of its calories from fat or a high-fat diet with 60% of calories from fat.
Results published in the November 5, 2014, online edition of the journal Diabetes revealed that mice lacking Sesn3 had elevated fasting blood glucose levels, indicative of impaired liver insulin sensitivity or poorly regulated glucose metabolism. Insulin and glucose tolerance tests were significantly improved in Sesn3-positive control mice.
Biochemical analysis revealed that Sesn3 interacted with and activated mTORC2 (mechanistic target of rapamycin complex 2) and subsequently stimulated Akt phosphorylation at serine 473. These findings suggested that Sesn3 could activate Akt via mTORC2 to regulate liver insulin sensitivity and glucose metabolism.
Senior author Dr. X. Charlie Dong, associate professor of biochemistry and molecular biology at the Indiana University School of Medicine, said, "We wanted to show that Sestrin 3 had critical liver-specific functions. This is a very fascinating protein. It is not very big, but it functions in a very dynamic manner controlling glucose production and insulin sensitivity. It is an important regulator for glucose homeostasis."
Related Links:
Indiana University School of Medicine
Investigators at Indiana University School of Medicine (Indianapolis, USA) focused their attention on the protein Sestrin 3 (Sesn3). The gene for this protein in humans is located on chromosome 11q21. The sestrin family of proteins, of which Sesn3 is a member, comprises cysteine sulfinyl reductases, and they modulate peroxide signaling and antioxidant defense. These proteins selectively reduce or repair hyperoxidized forms of typical 2-cysteine peroxiredoxins (enzymes that metabolize peroxides) in eukaryotes.
Sestrin expression was found to be regulated by the tumor suppressor protein p53. Sesn3 was identified as a forkhead box O (FoxO) protein with antioxidant activity. Recently it was reported that Sesn3 may play an important role in Akt induced increase in reactive oxygen species (ROS), and it might be a promising target in selectively killing cancer cells containing high levels of Akt activity.
Akt, also known as protein kinase B (PKB), is a serine/threonine-specific protein kinase that plays a key role in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription, and cell migration. Akt is hyperactivated in cancer. This hyperactivity leads to an increase in intracellular ROS mainly by inhibiting the expression of ROS scavengers downstream of FoxO, such as Sesn3.
In the current study, the investigators generated Sesn3 liver-specific transgenic and knockout mice. These animals were fed a diet with 18% of its calories from fat or a high-fat diet with 60% of calories from fat.
Results published in the November 5, 2014, online edition of the journal Diabetes revealed that mice lacking Sesn3 had elevated fasting blood glucose levels, indicative of impaired liver insulin sensitivity or poorly regulated glucose metabolism. Insulin and glucose tolerance tests were significantly improved in Sesn3-positive control mice.
Biochemical analysis revealed that Sesn3 interacted with and activated mTORC2 (mechanistic target of rapamycin complex 2) and subsequently stimulated Akt phosphorylation at serine 473. These findings suggested that Sesn3 could activate Akt via mTORC2 to regulate liver insulin sensitivity and glucose metabolism.
Senior author Dr. X. Charlie Dong, associate professor of biochemistry and molecular biology at the Indiana University School of Medicine, said, "We wanted to show that Sestrin 3 had critical liver-specific functions. This is a very fascinating protein. It is not very big, but it functions in a very dynamic manner controlling glucose production and insulin sensitivity. It is an important regulator for glucose homeostasis."
Related Links:
Indiana University School of Medicine
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples